Bisphosphonate generally seems to be safe, but hypocalcemia may occasionally develop in the course of bisphosphonate treatment. Hypocalcemia induced by bisphosphonate is usually mild and asymptomatic, but unrecognized or poorly treated hypocalcemia can lead to life-threatening state. A 78-year-old woman who had a history of hip arthroplasty and intravenous zoledronate treatment for femur neck f...

BACKGROUND Although bisphosphonate is effective for the prevention and treatment of osteoporosis, poor medication compliance is a key-limiting factor. We determined whether alarm clock could improve compliance with weekly bisphosphonate in patients with osteoporosis, by comparing with age- and gender-matched control group. METHODS Fifty patients with osteoporosis were recruited and participat...

+Donnelly, E; Meredith, DS; Gladnick, BP; Rebolledo BJ; Lane JM; Boskey, AL +Hospital for Special Surgery, New York, NY [email protected] INTRODUCTION Bisphosphonate therapy reduces fracture incidence in osteoporotic patients, and the safety and efficacy of alendronate is generally preserved with treatment durations as long as 10 years [1]. Although no significant association between bisphosphona...

After discontinuation of bisphosphonate therapy, an antiresorptive effect and antifracture protection persist for an undefined period. Patients are encouraged to continue calcium and vitamin D supplementation, during a bisphosphonate drug holiday. However, assessment of adequate calcium intake during the bisphosphonate drug holiday is difficult. Therefore, we measured the serum intact parathyro...

Bisphosphonates are widely used to treat children with osteogenesis imperfecta (OI), a bone fragility disorder that is most often caused by mutations in COL1A1 or COL1A2. However, it is unclear whether this treatment decreases the risk of developing scoliosis. We retrospectively evaluated spine radiographs and charts of 437 patients (227 female) with OI caused by mutations in COL1A1 or COL1A2 a...

Methods We sought individual patient data from all unconfounded trials in early breast cancer that randomised between bisphosphonate and control. Primary outcomes were recurrence, distant recurrence, and breast cancer mortality. Primary subgroup investigations were site of fi rst distant recurrence (bone or other), menopausal status (postmenopausal [combining natural and artifi cial] or not), a...

Osteonecrosis of the jaws following the use of bisphosphonate drugs has been reported in the literature. Presently, there is limited evidence to establish guidelines for the prosthodontic management of patients with active osteonecrosis, a history of osteonecrosis, or medical history of using these medications. This clinical report reviews the current literature regarding bisphosphonate use, an...

We present a case of a bisphosphonate-related femur fracture in an elderly woman, who failed treatment with both cephalomedullary nail and proximal femoral locking plate, leading to successful treatment with total hip arthroplasty. Hardware failure should be included in the differential of patients with previous internal fixation of bisphosphonate-related femur fracture that present with hip or...

Abstract Introduction This study aimed to determine the effects of denosumab treatment on joint destruction Japanese females with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (CCP) antibodies. Materials methods retrospective longitudinal included 56 patients treated 50 bisphosphonate. All participants were positive for anti-CCP also had a history osteoporosis bisphosphonate, ...

BACKGROUND Osteonecrosis of the jaws is increasing worldwide in patients treated with bisphosphonates. STUDY DESIGN A retrospective review of 52 patients who were treated during 2007-2010 for bisphosphonate related maxillofacial symptoms of the jaws was conducted. Patient characteristics and other factors that influenced the disease process were studied. RESULTS Thirteen patients received b...